SCHEMBL246748

SCHEMBL246748

CCCCN(CCCC)CCCNC(=N)NC(=N)N

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33
GRIN3A Q8TCU5 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
SPHK1 Q9NYA1 4/20 0.33
DNM1 Q05193 1/20 0.33
KDM5A P29375 3/20 0.32
ALDH1A1 P00352 2/20 0.32
ACHE P22303 2/20 0.32
ACKR3 P25106 1/20 0.32
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
KMT2A Q03164 1/20 0.31
SPHK2 Q9NRA0 1/20 0.31
PHF8 Q9UPP1 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL244333 0.88 ALDH1A1 (0.42) ALDH1A1ACHEACKR3KDM4ELMNA
SCHEMBL5158754 0.85 MEN1 (0.40) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL27451 0.85 GRIN2D (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL7999132 0.83 GRIN2D (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL15669256 0.83 GRIN2D (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL1560316 0.83 GRIN2D (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL6018 0.83 GRIN2D (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL3644254 0.83 GRIN2D (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL786167 0.83 SPHK1 (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Buformin SCHEMBL749659 0.83 GRIN2D (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012036392-A3 HUMAN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR FAB ANTIBODY AND A PHARMACEUTICAL COMPOSITION FOR TREATING TUMOURS COMPRISING THE SAME 주식회사 아이지세라피 (KR) 2012-05-10 WO claimed
EP-1930376-B1 CURABLE COMPOSITION KANEKA CORP (JP) 2011-12-07 EP claimed
EP-4692247-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2026-02-11 EP disclosed
US-20260022211-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2026-01-22 US disclosed
EP-4180482-B1 MOISTURE-CURABLE COMPOSITION NITTO KASEI CO LTD (JP) 2025-12-03 EP disclosed
EP-4656672-A1 METHOD FOR PRODUCING CURABLE COMPOSITION Kaneka Corporation (JP) 2025-12-03 EP disclosed
US-12479869-B2 Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product NITTO KASEI CO., LTD. (JP) 2025-11-25 US disclosed
EP-4174053-B1 CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT NITTO KASEI CO LTD (JP) 2025-11-19 EP disclosed
EP-4569023-A1 COMBINATION OF CATALYTIC COMPONENTS PolyU GmbH (DE) 2025-06-18 EP disclosed
EP-4105262-B1 CURABLE COMPOSITION AND CURED PRODUCT THEREOF KANEKA CORP (JP) 2025-04-02 EP disclosed
US-20240417559-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2024-12-19 US disclosed
US-20090182091-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2009-07-16 US disclosed
US-20090182099-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2009-07-16 US disclosed
US-20090171025-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2009-07-02 US disclosed
EP-1992665-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-11-19 EP disclosed
EP-1990370-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-11-12 EP disclosed
EP-1988127-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-11-05 EP disclosed
EP-1985666-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-10-29 EP disclosed
EP-1939257-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-07-02 EP disclosed
EP-1930376-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479869-B2 Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product KDM2B, SETDB1, ASH2L GRIN2D 3200/4885GRIN3B 2391/4885GRIN1 1411/4885
US-20260022211-A1 CURABLE COMPOSITION H1-4, H1-0, H1-2 GRIN2D 1604/4885GRIN3B 1996/4885GRIN1 1109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.